Bilfinger supports leading healthcare company with Corona vaccine production


Bilfinger has supported one of the world’s largest biomedical companies with modifications of one of their plants for the industrial production of a Corona virus vaccine. The contract marks an extension and an expansion of an existing framework agreement with the customer. 

“We are honored to support a long-standing customer in the fight against COVID-19 with our expertise in designing and modifying biopharma plants,” says Christina Johansson, interim CEO and CFO at Bilfinger. “Our experience in the industry and customer-specific knowledge were key factors in winning this contract. Being already onsite, we could rapidly provide the personnel, proficiency and flexibility required for this time-critical project.” 

A team from Bilfinger Tebodin, with up to 40 employees on site and up to 60 in the back office, has been supporting the customer with various smaller modification projects at their pharmaceutical production plant for the past six years. At the beginning of 2021, the framework agreement was extended for another year. During the plant modification stage, the Bilfinger team also took over some additional non-vaccine related projects, allowing the customer to focus on getting the vaccine production up and running. 

With an experienced team involved in pharmaceutical and biotech projects, the multidisciplinary consulting and engineering firm Bilfinger Tebodin executes projects for the European  (bio-)pharmaceutical industry. 

Read the full press release by clicking on the image below: